PARIS, Jan. 14, 2025 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has…Read More
You might also be interested in reading Stran outlines accelerated margin expansion and organic growth focus for 2025 while integrating Gander Group acquisition.